Endo promotes Coleman to CEO, names new CFO
Endo’s CEO succession plan — announced in November 2019 — is complete. The company has named Blaise Coleman, who has been executive vice president and CFO since 2016, ot the dual role of president and CEO. He succeeds Paul Campanelli, who will continue as chairman of the board of directors, which Coleman will officially join March 6.
Additionally, Mark Bradley will succeed Coleman as executive vice president and CFO. Bradley is currently Endo's senior vice president, corporate development and treasurer.
As a critical member of the executive leadership team, Endo said Coleman has successfully executed multiple enterprise-wide strategic initiatives during its multi-year transformation resulting in enhanced capabilities, operating simplification, and margin improvements.
"Blaise is uniquely qualified to lead Endo's continued transformation. In addition to his comprehensive financial background, Blaise has a successful track record of building high-performing teams and delivering strong results," Campanelli said. "His proven business leadership, extensive pharmaceutical expertise and deep understanding of the issues facing the industry make him the ideal leader to leverage the company's strong operating performance to drive future growth."
Coleman has more than 20 years of pharmaceutical industry experience. Prior to joining Endo in 2015, he held a number of leadership roles of increasing responsibility with AstraZeneca and Johnson & Johnson. He began his career at PricewaterhouseCoopers.
"I am honored to build on Paul's legacy and excited to lead Endo in its next phase. I believe Endo has significant opportunities to create shareholder value and become the company we aspire to be over the long term," said Coleman. "I would like to thank Paul and the board for the opportunity to serve Endo's team members, patients and shareholders."
Since joining Endo in 2007, Coleman's successor in the CFO role, Bradley, has held several financial and strategic development leadership positions. Prior to joining Endo, he served as a management consultant, most recently with Deloitte Consulting, and started his career at Ernst & Young.
"Mark has over 25 years of broad financial and corporate development experience. His proven ability to successfully lead strategic initiatives and drive business value, while focusing on optimizing liquidity and capital structure will play a critical role in Endo's future success," said Coleman.
"I look forward to continuing to work with Blaise and the rest of the team to achieve Endo's strategic and business objectives," Bradley said.
Endo also announced Mark Barberio will serve as a director of the board, effective Feb. 19, 2020. Barberio also has been appointed to Endo's audit committee and its nominating and governance committee.
Barberio is the principal of Markapital, a business and merger and acquisition consulting firm. Prior to founding Markapital, he led Mark IV (now Dayco), a global diversified manufacturing company, where he served in a number of leadership positions, including as its co-CEO and chief financial officer.
"In addition to Mark's senior executive leadership experience, Mark's operations, finance and strategic planning perspective on corporate growth will provide valuable insight to the board," said Campanelli, adding, "We are pleased to welcome him to our board."